AVADEL PHARMACEUTICALS PLC 4

Geoffrey Michael Glass, an Avadel Pharmaceuticals plc insider, disposed of all directly and trust‑held ordinary shares and multiple option awards in connection with Avadel’s $21.00‑per‑share cash‑and‑CVR acquisition by Alkermes plc.

On February 12, 2026, Geoffrey Michael Glass reported the automatic disposition of all of his Avadel Pharmaceuticals plc ordinary shares and stock options inidenced by a company sale to Alkermes plc under a scheme of arrangement. A total of 220,05 directly held ordinary shares and 145,979 shares held indirectly through trusts (69,075 and 75,904 shares in two separate trusts) were converted into the right to receive $21.00 per share in cash plus a contingent value right (CVR) for up to an additional $1.50 per share, implying gross share consideration of roughly $7.7 million excluding CVR value. In addition, multiple tranches of stock options with exercise prices ranging from $2.03 to $16.32 over 241,000 underlying shares were canceled and converted into cash equal to the in‑the‑money value based on the $21.00 merger price plus one CVR per underlying share, also as part of the acquisition. Post‑transaction, the reporting person no longer holds Avadel equity, and the activity reflects closing of a corporate change‑of‑control rather than discretionary insider trading.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

sec

Accession

0001104659-26-014443

Alert Tier

6